Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o.

The medical center is at the forefront of research in metastatic colorectal cancer, focusing on innovative treatment strategies for patients who are not candidates for intensive therapy.

• Progression-Free Survival (PFS) Enhancement
• Investigator-Assessed Treatment Efficacy

By exploring novel drug combinations, the center aims to improve patient outcomes and extend survival rates.

Specializing in follicular lymphoma and marginal zone lymphoma, the center is dedicated to advancing therapeutic options for relapsed or refractory cases.

• Combination Therapy Efficacy
• Comparative Treatment Analysis

Research efforts are directed towards optimizing treatment regimens to enhance patient response and quality of life.

The center is pioneering research in limited stage small-cell lung cancer, focusing on the efficacy of novel immunotherapies.

• Durvalumab and Tremelimumab Efficacy
• Overall Survival (OS) Improvement

Through cutting-edge clinical trials, the center aims to establish new standards of care for this challenging condition.

With a focus on hormone receptor-positive, HER2-negative breast cancer, the center is exploring advanced treatment options for inoperable or metastatic cases.

• Superiority of Dato-DXd
• Overall Survival (OS) and PFS

Research is aimed at improving therapeutic outcomes and providing new hope for patients with limited treatment options.

Specializing in adenocarcinoma of the biliary tract, the center is investigating post-surgical chemotherapy regimens to delay cancer recurrence.

• Recurrence-Free Survival (RFS)
• Post-Surgical Treatment Safety

The center's research is pivotal in developing strategies to enhance long-term survival and quality of life for patients.

Focusing on locally advanced head and neck squamous cell carcinoma, the center is evaluating the efficacy of novel therapies post-chemoradiotherapy.

• Volrustomig Efficacy
• Progression-Free Survival (PFS)

Research aims to establish new therapeutic protocols that improve patient outcomes and reduce recurrence rates.

The center is advancing research in stage III and IV melanoma, focusing on the efficacy of combination therapies for treatment-resistant cases.

• Objective Response Rate (ORR)
• Combination Therapy Efficacy

By exploring innovative treatment combinations, the center seeks to improve survival rates and patient quality of life.

Specializing in HER2-expressing gastric and esophageal cancer, the center is evaluating the safety and efficacy of novel drug combinations.

• Antitumor Activity Assessment
• Phase 2 Dose Determination

Research efforts are focused on developing targeted therapies that offer improved outcomes for patients with advanced disease.

The center is at the forefront of research in epithelial ovarian cancer, particularly in cases that have progressed on prior PARP inhibitor therapy.

• Combination Therapy Efficacy
• Safety and Tolerability Evaluation

By investigating new therapeutic combinations, the center aims to enhance treatment efficacy and patient survival.

Focusing on peripheral T-cell lymphoma, the center is conducting trials to evaluate the efficacy of novel drug combinations in newly diagnosed patients.

• Progression-Free Survival (PFS) Comparison
• Optimal Dose Selection

Research is aimed at improving therapeutic outcomes and establishing new standards of care for this aggressive cancer type.